This article provides a detailed framework for implementing robust Immunohistochemistry (IHC) controls in predictive biomarker assays, essential for precision medicine and drug development.
This article provides researchers, scientists, and drug development professionals with a systematic framework for interpreting immunohistochemistry (IHC) controls to effectively reduce background staining.
This article provides researchers, scientists, and drug development professionals with a comprehensive analysis of the concordance between Immunohistochemistry (IHC) and molecular testing methods.
This comprehensive review examines the critical role of external quality assessment (EQA) in establishing and validating immunohistochemistry (IHC) concordance rates for predictive biomarkers.
This comprehensive guide addresses the persistent challenge of high background staining in immunohistochemistry (IHC), particularly in problematic tissues rich in endogenous molecules and autofluorescence.
This comprehensive guide for researchers and drug development professionals addresses the pervasive challenge of background staining in Immunohistochemistry (IHC).
This comprehensive guide explores Immunohistochemistry (IHC) background staining, a critical factor impacting data reliability in biomedical research and drug development.
This comprehensive guide details the critical process of verifying FDA-approved IHC assays within a CLIA laboratory environment.
This comprehensive guide clarifies the critical distinctions between single-site In Vitro Diagnostic (IVD) and multi-site Clinical Laboratory Improvement Amendments (CLIA) validation pathways for immunohistochemistry (IHC) assays.
This comprehensive article provides researchers, scientists, and drug development professionals with an actionable roadmap for immunohistochemistry (IHC) assay validation aligned with College of American Pathologists (CAP) guidelines.